Molecular design of novel PGI2 agonists without PG skeleton. III-Reference-Cited by-同舟云学术

Molecular design of novel PGI2 agonists without PG skeleton. III

Published:1995-05 Issue:10 Volume:5 Page:1077-1082
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Hamanaka Nobuyuki,Takahashi Kanji,Nagao Yuuki,Torisu Kazuhiko,Tokumoto Hidekado,Kondo Kigen

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference4 articles.

1. Ciloprost

2. TRK-100

3. For Part II, see: Hamanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Takada, H.; Tokumoto, H.; Kondo, K. Bioorg. Med. Chem. Lett., preceding paper in this issue.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ChemInform Abstract: Molecular Design of Novel PGI2 Agonists Without PG Skeleton. Part 3.;ChemInform;2010-08-17

2. Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6;Bioorganic & Medicinal Chemistry Letters;2006-09

3. Discovery of Novel Prostacyclin Mimetics with Highly Potent and Selective IP Receptor Agonists;Journal of Synthetic Organic Chemistry, Japan;2006

4. Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2;Bioorganic & Medicinal Chemistry Letters;2005-07

5. Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3;Bioorganic & Medicinal Chemistry Letters;2005-06